Science

Applied Clinical Trials

by Applied Clinical Trials

Claiming needs an RSS feed. Contact us.

Listen on Apple Podcasts

Recently ranked · United States

Last recorded placements from this show’s chart history. These are not current rankings.

Not on the United States charts we track today.

If you like Applied Clinical Trials, try…

Live Trials with Emily D. Baker

Latest episodes

ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act

October 23, 2026 · 2 min

In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit

October 22, 2026 · 2 min

In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
ACT Brief: AI Operating Models, Oncology Evidence Trust, and Thyroid Eye Disease Approval

October 19, 2026 · 1 min

In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
ACT Brief: Who Sets Trial Endpoints, Human-Centered Trial Execution, and Bladder Cancer Approval Expansion

October 16, 2026 · 2 min

In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution

October 15, 2026 · 39 min

In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO…

Show 7 more episodesShow fewer episodes

ACT Brief: EHR-to-EDC Connectivity, FDA’s Rare Disease Framework, and Barriers to Oncology RWE

October 15, 2026 · 2 min

In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License

October 14, 2026 · 2 min

In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity…
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?

October 9, 2026 · 27 min

Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Applied Clinical Trials podcast, Matt Walz, CEO…
ACT Brief: RBQM Analysis Frequency, Building Trust in Oncology Data, and Rare Pediatric PRV Monetization

October 9, 2026 · 2 min

In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs

October 8, 2026 · 2 min

In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction

October 7, 2026 · 2 min

In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
ACT Brief: Ibogaine Trial Design Guidance, Outsourcing Model Oversight Gaps, and Kidney Disease Partnership

October 6, 2026 · 2 min

In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.